Authors
Latest:
Alicia Morgans, MD, MPH, Discusses Outcomes From the CARD Trial in mCRPC at 2021 ESMOCancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.
Latest:
Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk StratificationThis study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Latest:
Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled TrialsThe aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.
Latest:
Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROCA phase 2 trial found that pembrolizumab plus lenvatinib elicited an overall response rate of 37.5% that consisted entirely of partial responses in high-grade serous PROC.
Latest:
CAR T, Targeted Therapies, Others as Treatment Options on the Horizon in NETsThe NETRF lends funding to help discover new and emerging treatment options in neuroendocrine tumors, according to Anna Greene, PhD.
Latest:
Emerging Strategies to Manage Relapsed and/or Refractory Multiple MyelomaJames J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature ReviewInvestigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
Latest:
Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood CancerRahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.
Latest:
Nadunolimab Earns FDA Fast-Track Designation in Metastatic PDACThe FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.
Latest:
Disorders of Sex Development and Malignant Germ Cell TumorsKey points: Patients with disorders of sex development (DSDs) are at an increased risk of malignant germ cell tumors (GCTs). In adulthood, the partial form of androgen insensitivity syndrome confers the greatest risk of developing malignant GCTs. Gonadoblastoma is the most common gonadal GCT arising in patients with DSDs. Despite being a benign neoplasm, it can undergo malignant transformation in up to 60% of patients with a DSD. Oncologic treatment in patients with disorders of sex development and malignant GCTs does not differ from the standard treatment for testicular GCTs. Treatment of patients with DSDs requires a multidisciplinary team, including a psychiatric, genetic, and reproductive assessment as well as the involvement of an ethics committee. An early diagnosis of DSDs is crucial to avoid the development of potentially serious complications in adulthood.
Latest:
Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited InstitutionsSurgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.
Latest:
Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-CelPanelists discuss how, for a patient who has an aggressive disease, physicians will plan for monthly serum markers including serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE); if they start seeing an increase in the disease, they plan an imaging for bone marrow biopsy and consider a diagnostics lumbar puncture.
Latest:
Precision Active Surveillance: Leveraging Genomic Testing and CCR Scores in Prostate Cancer ManagementDaniel Kim, MD, MBA discusses how genomic testing has revolutionized patient selection for active surveillance by integrating molecular insights that transcend traditional clinical parameters, enabling more nuanced risk stratification and personalized management of intermediate-risk prostate cancer.
Latest:
Cara Mathews, MD, Talks Dostarlimab for Advance Recurrent Endometrial CancersCara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.
Latest:
Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple MyelomaInvestigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.
Latest:
Key Takeaways on the Management of Clear-Cell RCCIn closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.
